EndoGENE – Ovagene Oncology


What Role Do Genes Play?

The medications you take rely on internal mechanisms to metabolize and transport them throughout your body. During this process, thousands of protein molecules interact with them and may alter how well they work. This means that your genes may affect how effectively (or ineffectively) you absorb and metabolize a particular drug, which in turn affects how well the drug works for you.

Therefore, the genetic make-up alters the individual’s response to drugs.

While medications may work well for most people, in certain people, a medication may not work or it may cause troublesome side effects. Knowing a patient’s genetic code may, therefore, assists the physician in making an informed treatment decision.

How Does This Affect Anticancer Drugs?

In cancer care the need to know whether a drug will or will not work is vitally important, both because these drugs often produce serious side effects and because the time it takes to prove a drug ineffective may allow cancer cells to grow or metastasize.

Pharmacogenomic testing for endometrial cancer

In endometrial cancer, all stages of disease are treated via surgery followed by surgical staging to generate pathological and prognostic data for treatment decision. In early stage cases, patients may also receive radiation but many are monitored over the few next years. High risk early stage patients are additionally treated with radiation and/or chemotherapy.

Later stage or recurrent endometrial cancer patients are also treated with chemotherapy. NCCN guidelines currently recommends 18 different therapy regimens from which the doctor may choose.

While there is no strict first line therapy regimen in case of endometrial cancer platinum and texane are the primary choice but there is flexibility in treatment decision based on histology, grade, stage and other clinical factors.

Integrating individual tumor genetics into the treatment decisions improves response and outcome.


Each person’s cancer and response to treatment is unique.

Assessment of an individual patient’s predisposition to drugs is essential to achieve the goal of personalized medicine in cancer therapy. EndoGENE Test from Ovagene Oncology uses genomic technology to understand the effects of all relevant genes on the behaviour of a drug or conversely the effect of a drug on gene expression.

EndoGENE™ Therapy Response/Recurrence Profile

In High Risk Endometrial Cancer

High risk early stage endometrial cancer is identified through a combination of histological and clinical factors. In general, high risk patients receive radiation, chemotherapy, or both as the disease and clinical factors indicate that the cancer may be more aggressive.

EndoGENE test can be used to exclude therapy options with resistance markers thus reducing unnecessary side effects and complications from ineffective therapies. In high risk endometrial patients, the doctor may order the test at the time of surgery or soon after the final diagnosis is provided by their pathology service in order to have results in time to treat the patient appropriately.

EndoGENE includes biomarkers for response to tamoxifen and aromatase inhibitors. In this case, the assay could be used to recommend chemotherapy for patients not likely to respond to hormone therapy or recommend a course of hormone therapy instead of the more toxic chemotherapy.

In Low Risk Endometrial Cancer

The use of EndoGENE to prioritize and select drugs based on the genetics of an individual’s tumor could further improve outcome while reducing side effects and unnecessary morbidity from ineffective treatment regimens.

In the recurrent case, the use of EndoGENE could be used to prioritize drugs in a setting where gaining a response in a short amount of time is critical to improving outcome.

Kay’s Array™ Targeted Therapies Panel

Quantitative gene expression assay that examines the protein expression of select genes associated with response to a variety of targeted drugs. The assay is clinically useful in the treatment of late stage and recurrent cervical cancer since there is a broader list of therapeutic options to consider including targeted therapies.

Key Opinion Leaders thoughts from USA on Ovagene Gynecologic Panels:

1

Veronica L. Schimp. D.O. FACOG
Chief, Gynecology Oncology
MD Anderson Cancer Center Orlando

“We have worked with OvaGene for two years. OvaGene offers timely, efficient services, and provide critical information for helping decisions for our patients. We are pleased to support OvaGene’s growth and the key role they play in gynecologic cancer patient care.”

2

Jonathan M. Lancaster, MD PhD
President, Moffitt Medical Group
Chair, Department of Women’s Oncology
Moffitt Cancer Center

“Ovagene Oncology has been in the forefront of molecular diagnostics for gynecologic cancer, a field that is just now unfolding as we explore options for truly personalized oncology care for women with gynecologic cancer. Given that most women with ovarian cancer suffer recurrennce of disease, and that only a fraction of drugs have activity for an individual tumor, along with interest in new targeted (and also very expensive) therapies, it becomes imperative that we improve a patient’s odds for response to theraphy through study of the patient’s own unique tumor gene signatures. Ovagene’s clinical performance with quick turnaround and telephone support for diagnostic assistance have been exemplary.”

3

Robert Holloway. MD
Co-Director of Gynecologic Oncology
Florida Hospital Cancer Institute
Professor of OB-Gyn, University of Central Florida

Tab content
Tab content

WE WOULD LOVE TO HEAR FROM YOU

Contact us